Majid, Salmiya .

HRN: 06-68-02  Sex: Female

Patient Encounter


Audit Details

Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
04/24/2025
CO-AMOXICLAV 625MG (TAB)
04/24/2025
04/30/2025
P0
625mg
BID
G1P0 PU 39 3/7 Weeks AOG; T/c Dengue Fever With WS
Waiting Final Action 

Indication:  Prophylaxis    Type of Infection:  Skin & Soft Tissue    Compliance to guidelines: Compliant To Guidelines

Initial appropriateness: Yes   

Final appropriateness: Yes   

Overall appropriateness: Yes 

Intervention



Type of Intervention done:

                    

           


Acceptance: